Bone and brain metastasis in lung cancer: Recent advances in therapeutic strategies

Therapeutic Advances in Medical Oncology

Volumn 6, Issue 3, 2014, Pages 101-114

  D’antonio, Chiara ^a   Passaro, Antonio ^b   Del Signore, Ester ^b   Marinis, Filippo ^b   Gori, Bruno ^c   Migliorino, Maria Rita ^c   Ricciardi, Serena ^c   Fulvi, Alberto ^c  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c Oncological Pulmonary 1st Unit   (Italy)

Author keywords

afatinib; bone; brain; epidermal growth factor; erlotinib; gefitinib; lung cancer; metastases

Indexed keywords

AFATINIB; ANGIOGENESIS INHIBITOR; DENOSUMAB; DEXAMETHASONE; ERLOTINIB; GEFITINIB; ZOLEDRONIC ACID;

BONE METASTASIS; BONE PAIN; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; HUMAN; HYPERCALCEMIA; LOCAL THERAPY; LUNG CANCER; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SYSTEMIC THERAPY; TREATMENT RESPONSE;

EID: 84899018415     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834014521110     Document Type: Review

References (92)

1. Abrey L. Olson J. Raizer J. Mack M. Rodavitch A. Boutros D. et al. (2001) A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 53: 259–265.
2. Anse'n S. Bangard C. Querings S. Gabler F. Scheffler M. Seidel D. et al. (2010) Osteoblastic response in patients with non-small cell lung cancer with activating EGFR mutations and bone metastases during treatment with EGFR kinase inhibitors. J Thorac Oncol 5: 407–409.
3. Antonadou D. Paraskevaidis M. Sarris G. Coliarakis N. Economou I. Karageorgis P. et al. (2002). Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 20: 3644–3650.
4. Attia A. Rapp S. Case L. D'Agostino R. Lesser G. Naughton M. et al. (2012) Phase II study of Ginkgo biloba in irradiated brain tumor patients: effect on cognitive function, QOL, and mood. J Neurooncol 109: 357–363.
5. Barlesi F. Gervais R. Lena H. Hureaux J. Berard H. Paillotin D. et al. (2011) Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). Ann Oncol 22: 2466–2470.
6. Bearz A. Garassino I. Tiseo M. Caffo O. Soto-Parra H. Boccalone M. et al. (2010) Activity of pemetrexed on brain metastases from non-small cell lung cancer. Lung Cancer 68: 264–268.
7. Berenson J. Rajdev L. Broder M. (2006) Managing bone complications of solid tumors. Cancer BiolTher 5: 1086–1089.
8. Bernardo G. Cuzzoni Q. Strada M. Bernardo A. Brunetti G. Jedrychowska I. et al. (2002) First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase II study. Cancer Invest 20: 293–302.
9. Botteman M. Foley I. Marfatia A. Brandman J. Langer C. (2007) Economic value of Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer: the case of the United Kingdom (UK). J Clin Oncol 25: 6617.
10. Boyle W. Simonet W. Lacey D. (2003) Osteoclast differentiation and activation. Nature 423: 337–342.
11. Bruera E. Neumann C. (1999) Bone pain. In: ASCO Educational Book. Philadelphia: W.B. Saunders, pp. 393–401.
12. Butler J. Jr Case L. Atkins J. Frizzell B. Sanders G. Griffin P. et al. (2007) A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys 69: 1496–1501.
13. Castrucci W. Knisely J. (2008) An update on the treatment of CNS metastases in small cell lung cancer. Cancer J 14: 138–146.
14. Ceresoli G. Cappuzzo F. Gregorc V. Bartolini S. Crinò L. Villa E. (2004) Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 15: 1042–1047.
15. Christodoulou C. Bafaloukos D. Kosmidis P. Samantas E. Bamias A. Papakostas P. et al. (2001) Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 12: 249–254.
16. Coleman R E. (1998) How can we improve the treatment of bone metastases further? Curr Opin Oncol 10 (1): S7–13.
17. Coleman R. (2000) Management of bone metastases. Oncologist 5: 463–470.
18. Coleman R. (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27: 165–176.
19. Cortes J. Rodriguez J. Aramendia J. Salgado E. Gurpide A. Garcia-Foncillas J. et al. (2003) Front-line paclitaxel / cisplatin based chemotherapy in brain metastases from non-small-cell lung cancer. Oncology 64: 28–35.
20. D'Addario G. Fruh M. Reck M. et al (2010) Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl. 5): 116–119.
21. Daubine F. Le Gall C. Gasser J. Green J. Clezardin P. (2007) Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 99: 322–330.
22. Delaney A. Fleetwood-Walker S. Colvin L. Fallon M. (2008) Translational medicine: Cancer pain mechanisms and management. Br J Anaesth 101: 87–94.
23. Delattre J. Krol G. Thaler H. Posner J. (1988) Distribution of brain metastases. Arch Neurol 45: 741–744.
24. Delea T. Langer C. McKiernan J. Liss M. Edelsberg J. Brandman J. et al. (2004) The cost of treatment of skeletal related events in patients with bone metastases from lung cancer. Oncology 67: 390–396.
25. Delea T. McKiernan J. Brandman J. Edelsberg J. Sung J. Raut M. et al. (2006) Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. J Thorac Oncol 1: 571–576.
26. de Luca A. Carotenuto A. Rachiglio A. Gallo M. Maiello M. Aldinucci D. et al. (2008) The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 214: 559–567.
27. Dhruva N. Socinski M. (2009) Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib. J Clin Oncol 27: e31–e32.
28. Edelman M. Belani C. Socinski M. Ansari R. Obasaju C. Chen R. et al. (2010) Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. J Thorac Oncol 5: 110–116.
29. Fallon M. (2013) Neuropathic pain in cancer. Br J Anaesth 111: 105–111.
30. Fournier P. Chirgwin J. Guise T. (2006) New insights into the role of T cells in the vicious cycle of bone metastases. Curr Opin Rheumatol 18: 396–404.
31. Galetta D. Gebbia V. Silvestris N. Ferraù F. Carrozza F. Cigolari S. et al. (2011) Cisplatin, fotemustine and whole-brain radiotherapy in non-small cell lung cancer patients with asymptomatic brain metastases: a multicenter phase II study of the Gruppo Oncologico Italia Meridionale (GOIM 2603). Lung Cancer 72: 59–63.
32. Giorgio C. Giuffrida D. Pappalardo A. Russo A. Santini D. Salice P. et al. (2005) Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study. Lung Cancer 50: 247–254.
33. Green J. (2003) Antitumor effects of bisphosphonates. Cancer 97: 840–847.
34. Hanks GW. (1988) Cancer pain–the problem areas. Cancer Surv 7 (1): 1–4.
35. Harita S. Mizuta A. Kuyama S. Kikuchi T. (2005) Long-term survival following concurrent chemoradiotherapy in patients with non-small cell lung cancer with concomitant brain metastases only. Int J Clin Oncol 10: 63–68.
36. Henry D. Costa L. Goldwasser F. (2011 a) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29: 1125–1132.
37. Henry D. Costa L. Goldwasser F. Hirsh V. Hungria V. Prausova J. et al. (2011 b) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29: 1125–1132.
38. Hirsh V. Saad F. Lipton A. (2008) Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 3: 228–236.
39. Hirsh V. Tchekmedyian N. Rosen L. Zheng M. Hei Y. (2004) Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer 6: 170–174.
40. Hotta K. Kiurab K. Ueokaa K. Tabatab M. Fujiwarab K. Kozukia T. (2004) Effect of gefitinib (‘Iressa’, ZD1839) on brainmetastases in patients with advanced non-small-cell lung cancer. Lung Cancer 46: 255–261.
41. Hu X. Zou Q. Jin C. Li W. Chen W. Ma L. (2010) Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers. Nan Fang Yi Ke Da Xue Xue Bao 30: 1343–1346.
42. Kim D. Lee K. Yun T. Kim D. Kim T. Heo D. et al. (2005) Efficacy of platinum chemotherapy after cranial irradiation in patients with brain metastasis from non-small cell lung cancer. Oncol Rep 14: 207–211.
43. Kim J. Lee D. Choi Y. Yoon D. Kim S. Suh C. et al. (2009) Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 65: 351–354.
44. Kim K. Lee J. Lee J. Nam D. Kong D. Ahn Y. et al. (2010) Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases. Lung Cancer 68: 258–263.
45. Kolaczkowska M. Junik R. Rzymkowska M. Kramer L. (1998) The effect of chemotherapy on bone metabolism in patients with non-small cell lung cancer. Pneumonol Alergol Pol 66: 283–289.
46. Kong Y. Feige U. Sarosi I. Bolon B. Tafuri A. Morony S. et al. (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis throughcosteoprotegerinlegand. Nature 402: 304–308.
47. Kosteva J. Langer C. (2008) The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancer. Curr Opin Oncol 20: 155–161.
48. Lewis M. Hendrickson A. Moynihan T. (2011) Oncologic emergencies: pathophysiology, presentation, diagnosis, and treatment. CA Cancer J Clin 61: 287–314.
49. Lu X. Kang Y. (2010) Epidermal growth factor signalling and bone metastasis. Br J Cancer 102: 457–461.
50. Lu X. Wang Q. Hu G. van Poznak C. Fleisher M. Reiss M. et al. (2009) ADAMTS 1 and MMP 1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev 23: 1882–1894.
51. Major P. Lortholary A. Hon J. Abdi E. Mills G. Menssen H. et al. (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19: 558–567.
52. Matsumoto S. Kimura S. Segawa H. Kuroda J. Yuasa T. Sato K. et al. (2005) Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 47: 31–39.
53. McCormack K. (1994) Non-steroidal anti-inflammatory drugs and spinal nociceptive processing. Pain 59: 9–43.
54. Mikkelsen T. Paleologos N. Robinson P. Ammirati M. Andrews D. Asher A. et al. (2010) The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96 97–102.
55. Miller V. O'Connor P. Soh C. Kabbinavar F. for the ATLAS Investigators (2009) A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 27(Suppl. 18): 799s [abstract LBA8002].
56. Moscetti L. Nelli F. Felici A. Rinaldi M. de Santis S. D'Auria. (2007) GUp-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases: survey by Outcome Research Network for Evaluation of Treatment Results in Oncology. Cancer 15; 109 (2): 274–81.
57. Mundy G. (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2: 584–593.
58. Neuhaus T. Ko Y. Muller R. Grabenbauer G. Hedde J. Schueller H. et al. (2009) A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. Br J Cancer 100: 291–297.
59. Normanno N. Gullick W. (2006) Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application? Endocr-Relat Cancer 13: 3–6.
60. Okano Y. Nishio M. (2008) Efficacy of gefitinib in treatment of lung cancer patients with bone metastasis. Clin Calcium 18: 527–533.
61. Park S. Kim H. Lee D. Kim K. Kim S. Suh C. et al. (2012). Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer 77: 556–560.
62. Patchell R. Tibbs P. Walsh J. Dempsey R. Maruyama Y. Kryscio R. et al. (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322: 494–500.
63. Pluquet E. Cadranel J. Legendre A. Faller M. Souquet P. Zalcman G. et al. (2010) Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival. J ThoracOncol 5: 491–496.
64. Qu X. Huang X. Yan W. Wu L. Dai K. (2012) A meta-analysis of FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Eur J Radiol 81: 1007–1015.
65. Ripamonti C. Fulfaro F. (2010). Malignant bone pain: pathophysiology and treatments. Curr Rev Pain 4 (3):187–96.
66. Robinson P. Kalkanis S. Linskey M. Santaguida P. (2010) Methodology used to develop the AANS / CNS management of brain metastases evidence-based clinical practice parameter guidelines. J Neurooncol 96: 11–16.
67. Robinet G. Thomas P. Léna H. Gouva S. Dabouis G. (2001) Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1. Ann Oncol 12 (1): 59–67.
68. Rogers M. Gordon S. Benford H. Coxon F. Luckman S. Monkkonen J. et al. (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88(Suppl. 12): 2961–2978.
69. Rosen L. Gordon D. Tchekmedyian N. Yanagihara R. Hirsh V. Krzakowski M. et al. (2004) Long term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non small cell lung carcinoma and other solid tumors: a randomized, phase III, double blind, placebo-controlled trial. Cancer 100: 2613–2621.
70. Rosen L. Gordon D. Tchekmedyian S. Yanagihara R. Hirsh V. Krzakowski M. et al. (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial- the Zoledronic Acid Lung Cancer and other Solid Tumors Study Group. J Clin Oncol 21: 3150–3157.
71. Saad F. Lipton A. Cook R. Chen Y. Smith M. Coleman R. (2007) Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110: 1860–1867.
72. Sandler A. Hirsh V. Reck M. von Pawel J. Akerley W. Johnson D. (2012) An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases. Lung Cancer 78: 1–7.
73. Santini D. Vincenzi B. Avvisati G. Dicuonzo G. Battistoni F. Gavasci M. et al. (2002) Pamidronate induces modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 8: 1080–1084.
74. Santini D. Vincenzi B. Galluzzo S. Battistoni F. Rocci L. Venditti O. et al. (2003) ZA induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9: 2893–2897.
75. Schouten L. Rutten J. Huveneers H. Twijnstra A. (2002) Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94: 2698–2705.
76. Schwer A. Gaspar L. (2006) Update in the treatment of brain metastases from lung cancer. Clin Lung Cancer 8: 180–186.
77. Sekine I. Nokihara H. Yamamoto N. Kunitoh H. Ohe Y. Tamura T. (2009) Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy. Lung Cancer 65: 219–222.
78. Shaw E. Rosdhal R. D'Agostino R. Jr Lovato J. Naughton M. et al. (2006) Phase II study of donepezil in irradiated brain tumor patients: Effect on cognitive function, mood, and QOL. J Clin Oncol 24: 1415–1420.
79. Socinski M. Langer C. Huang J. Kolb M. Compton P. Wang L. et al. (2009) Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 27: 5255–5261
80. Song J. Oh Y. Shim T. Kim W. Ryu J. Choi C. (2009) Efficacy comparison between 18 F-FDG PET / TC and bone scintigraphy in detecting bone metastases of non-small cell lung cancer. Lung Cancer 65: 333–338.
81. Sørense J. Hansen H. Hansen M. Dombernowsky P. (1988) Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol 6: 1474–1480.
82. Spizzo G. Seeber A. Mitterer M. (2009) Routine use of pamidronate in NSCLC patients with bone metastasis: results from a retrospective analysis. Anticancer Res 29: 5245–5249.
83. Stopeck A. Lipton A. Body J. Steger G. Tonkin K. de Boer R. et al. (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blinded study. J Clin Oncol 28: 5132–5239.
84. Sugiura H. Yamada K. Sugiura T. Hida T. Mitsudomi T. (2008) Predictors of Survival in patients with bone metastasis of Lung Cancer. Clin Orthop Relat Res 466: 729–736.
85. Sun J. Ahn J. Lee S. Kim JA. Lee J. Park YH. et al. (2011) Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases. Lung Cancer 71: 89–93.
86. Tabrizi M. Tseng C. Roskos L. (2006) Elimination mechanism of therapeutic monoclonal antibodies. Drug Discov Today 11: 81–88.
87. Thompson S. Tonge D. (2000) Bone cancer gain without the pain. Nat Med 6: 504–505.
88. Togashi Y. Masago K. Fukudo M. Terada T. Fujita S. Irisa K. et al. (2010) Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol 5: 950–955.
89. Tsuya A. Kurata T. Tamura K. Fukuoka M. (2007) Skeletal metastases in non small cell lung cancer: a retrospective study. Lung Cancer 57: 229–232.
90. Watanabe S. Bruera E. (1994) Corticosteroids as adjuvant analgesics. J Pain Symptom Manage 9: 442–445.
91. Weinfurt K. Li Y. Castel L. Saad F. Timbie J. Glendenning G. et al. (2005) The significance of skeletal related events for the health-related QOL of patients with metastatic prostate cancer. Ann Oncol 16: 579–584.
92. Zarogoulidis K. Boutsikou E. Zaragoulidis P. Eleftheriadou E. Kontakiotis T. Lithoxopoulou H. et al. (2009) The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer 125: 1705–1709.